REFERENCES

1. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. The Lancet 2013;381:242-55.

2. Ho CY, Day SM, Ashley EA, et al. Genotype and ifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe). Circulation 2018;138:1387-98.

3. Yotti R, Seidman CE, Seidman JG. Advances in the genetic basis and pathogenesis of sarcomere cardiomyopathies. Annu Rev Genomics Hum Genet 2019;20:129-53.

4. Davis J, Davis LC, Correll RN, et al. A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy. Cell 2016;165:1147-59.

5. Kehat I, Davis J, Tiburcy M, et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res 2011;108:176-83.

6. Pua CJ, Tham N, Chin CWL, et al. Genetic studies of hypertrophic cardiomyopathy in singaporeans identify variants in TNNI3 and TNNT2 That are common in Chinese patients. Circ Genom Precis Med 2020;13:424-34.

7. Mogensen J, Hey T, Lambrecht S. A Systematic review of phenotypic features associated with cardiac troponin I mutations in hereditary cardiomyopathies. Can J Cardiol 2015;31:1377-85.

8. Mogensen J, Murphy RT, Kubo T, et al. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:2315-25.

9. Hu J, Xiang Li J, Hong K, Xin Hu J, Brugada P, Shu Cheng X. Hypertrophic cardiomyopathy and planned in vitro fertilization. Genetic testing and clinical evaluation. Herz 2012;37:447-52.

10. Guo L, Su Y, Chen C, et al. The TNNI3 p.R186Q mutation is responsible for hypertrophic cardiomyopathy via promoting FASN-stimulated abnormal fatty acid metabolism. J Cardiovasc Aging 2023;3:6.

11. van der Velden J, Tocchetti CG, Varricchi G, et al. Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovasc Res 2018;114:1273-80.

12. Previs MJ, O'Leary TS, Morley MP, et al. Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy. Circ Heart Fail 2022;15:e009521.

13. Ranjbarvaziri S, Kooiker KB, Ellenberger M, et al. Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy. Circulation 2021;144:1714-31.

14. Wang Y, Pinto JR, Solis RS, et al. Generation and functional characterization of knock-in mice harboring the cardiac troponin I-R21C mutation associated with hypertrophic cardiomyopathy. J Biol Chem 2012;287:2156-67.

15. Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2021;397:2467-75.